TY - JOUR AU - Torre, L. A. AU - Bray, F. AU - Siegel, R. L. AU - Ferlay, J. AU - Lortet-Tieulent, J. AU - Jemal, A. PY - 2015 DA - 2015// TI - Global cancer statistics, 2012 JO - CA Cancer J Clin VL - 65 UR - https://doi.org/10.3322/caac.21262 DO - 10.3322/caac.21262 ID - Torre2015 ER - TY - JOUR AU - Kim, S. T. AU - Cristescu, R. AU - Bass, A. J. AU - Kim, K. M. AU - Odegaard, J. I. AU - Kim, K. PY - 2018 DA - 2018// TI - Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer JO - Nat Med VL - 24 UR - https://doi.org/10.1038/s41591-018-0101-z DO - 10.1038/s41591-018-0101-z ID - Kim2018 ER - TY - JOUR AU - Wang, F. H. AU - Shen, L. AU - Li, J. AU - Zhou, Z. W. AU - Liang, H. AU - Zhang, X. T. PY - 2019 DA - 2019// TI - The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer JO - Cancer Commun VL - 39 UR - https://doi.org/10.1186/s40880-019-0349-9 DO - 10.1186/s40880-019-0349-9 ID - Wang2019 ER - TY - JOUR AU - Wang, F. AU - Wei, X. L. AU - Wang, F. H. AU - Xu, N. AU - Shen, L. AU - Dai, G. H. PY - 2019 DA - 2019// TI - Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432 JO - Ann Oncol VL - 30 UR - https://doi.org/10.1093/annonc/mdz197 DO - 10.1093/annonc/mdz197 ID - Wang2019 ER - TY - JOUR AU - Parikh, A. R. AU - Leshchiner, I. AU - Elagina, L. AU - Goyal, L. AU - Levovitz, C. AU - Siravegna, G. PY - 2019 DA - 2019// TI - Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers JO - Nat Med VL - 25 UR - https://doi.org/10.1038/s41591-019-0561-9 DO - 10.1038/s41591-019-0561-9 ID - Parikh2019 ER - TY - JOUR AU - Forschner, A. AU - Battke, F. AU - Hadaschik, D. AU - Schulze, M. AU - Weissgraeber, S. AU - Han, C. T. PY - 2019 DA - 2019// TI - Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study JO - J Immunother Cancer. VL - 7 UR - https://doi.org/10.1186/s40425-019-0659-0 DO - 10.1186/s40425-019-0659-0 ID - Forschner2019 ER - TY - JOUR AU - Li, L. AU - Wang, Y. AU - Shi, W. AU - Zhu, M. AU - Liu, Z. AU - Luo, N. PY - 2019 DA - 2019// TI - Serial ultra-deep sequencing of circulating tumor DNA reveals the clonal evolution in non-small cell lung cancer patients treated with anti-PD1 immunotherapy JO - Cancer Med VL - 8 UR - https://doi.org/10.1002/cam4.2632 DO - 10.1002/cam4.2632 ID - Li2019 ER - TY - JOUR AU - Mariathasan, S. AU - Turley, S. J. AU - Nickles, D. AU - Castiglioni, A. AU - Yuen, K. AU - Wang, Y. PY - 2018 DA - 2018// TI - TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells JO - Nature. VL - 554 UR - https://doi.org/10.1038/nature25501 DO - 10.1038/nature25501 ID - Mariathasan2018 ER - TY - JOUR AU - Das, S. AU - Johnson, D. B. PY - 2019 DA - 2019// TI - Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors JO - J Immunother Cancer VL - 7 UR - https://doi.org/10.1186/s40425-019-0805-8 DO - 10.1186/s40425-019-0805-8 ID - Das2019 ER - TY - JOUR AU - Yao, L. AU - Jia, G. AU - Lu, L. AU - Bao, Y. AU - Ma, W. PY - 2020 DA - 2020// TI - Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors JO - Int Immunopharmacol VL - 85 UR - https://doi.org/10.1016/j.intimp.2020.106628 DO - 10.1016/j.intimp.2020.106628 ID - Yao2020 ER -